Nitrous Oxide-Oxygen
PreclinicalSmall molecule
Nitrous Oxide-Oxygen is one of 38 small molecule programs targeting Depression. It is currently in Preclinical.
2
Indications
2
Total Trials
0
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
42 competitors in Depression
#DrugCompanyPhaseTrials
1Cymbalta
Jazz PharmaceuticalsApproved
Brintellix
TakedaApproved
Ketalar
AAultman Health Foundation
Approved
Zoloft
VViatris Specialty LLC
Approved
Vraylar
AbbVieApproved
Prozac
VVitae Pharmaceuticals Inc., an Allergan affiliate
Approved
Wellbutrin
GGlaxo Dba Glaxosmithkline
Approved
Trexall
Jazz PharmaceuticalsApproved
Estrace
Novo NordiskApproved
Spravato
WWim Janssens
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Nitrous Oxide-Oxygen. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity Hospital, Tours